Sentinel node radiotracer shows early promise:
This article was originally published in Clinica
Executive Summary
A potentially new radiotracer for identifying lymphatic tissue during a sentinel node biopsy procedure has produced promising results in a preclinical trial. 99mTc(DTPA)-mannosyl-dextran, developed by a team from the University of California, San Diego, could dramatically enhance the diagnostic performance of the sentinel node technique in melanoma, breast and other cancers, says US firm, Neoprobe, of Dublin, Ohio. Neoprobe holds a licence option for the compound, which exhibited rapid injection site clearance and little accumulation in nodes other than the sentinel one, according to the trial, published in The Journal of Nuclear Medicine (June).